PL1963302T3 - Polimorfy inhibitora c-Met/HGFR - Google Patents

Polimorfy inhibitora c-Met/HGFR

Info

Publication number
PL1963302T3
PL1963302T3 PL06820988T PL06820988T PL1963302T3 PL 1963302 T3 PL1963302 T3 PL 1963302T3 PL 06820988 T PL06820988 T PL 06820988T PL 06820988 T PL06820988 T PL 06820988T PL 1963302 T3 PL1963302 T3 PL 1963302T3
Authority
PL
Poland
Prior art keywords
polymorphs
met
hgfr inhibitor
hgfr
inhibitor
Prior art date
Application number
PL06820988T
Other languages
English (en)
Inventor
Jingrong Jean Cui
Michelle Bich Tran-Dube
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1963302(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL1963302T3 publication Critical patent/PL1963302T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL06820988T 2005-12-05 2006-11-23 Polimorfy inhibitora c-Met/HGFR PL1963302T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74267605P 2005-12-05 2005-12-05
EP06820988A EP1963302B1 (en) 2005-12-05 2006-11-23 Polymorphs of a c-met/hgfr inhibitor
PCT/IB2006/003383 WO2007066185A2 (en) 2005-12-05 2006-11-23 Polymorphs of a c-met/hgfr inhibitor

Publications (1)

Publication Number Publication Date
PL1963302T3 true PL1963302T3 (pl) 2013-06-28

Family

ID=38123249

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06820988T PL1963302T3 (pl) 2005-12-05 2006-11-23 Polimorfy inhibitora c-Met/HGFR

Country Status (19)

Country Link
US (1) US8217057B2 (pl)
EP (1) EP1963302B1 (pl)
JP (1) JP4663619B2 (pl)
KR (1) KR101146852B1 (pl)
CN (1) CN101326175B (pl)
AR (1) AR057964A1 (pl)
AU (1) AU2006323025B2 (pl)
CA (1) CA2632283C (pl)
DK (1) DK1963302T3 (pl)
ES (1) ES2402419T3 (pl)
IL (1) IL191971A (pl)
NZ (1) NZ568289A (pl)
PL (1) PL1963302T3 (pl)
PT (1) PT1963302E (pl)
RU (1) RU2387650C2 (pl)
SI (1) SI1963302T1 (pl)
TW (1) TWI389902B (pl)
WO (1) WO2007066185A2 (pl)
ZA (1) ZA200804374B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122020017756B1 (pt) 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
DE602006018354D1 (de) * 2005-12-05 2010-12-30 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
WO2009099982A1 (en) * 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
JP2012509342A (ja) * 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
CA2808210C (en) * 2010-08-20 2019-10-01 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds having alk inhibitory activity and compositions thereof
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
EP2620140A1 (en) 2012-01-26 2013-07-31 ratiopharm GmbH Crizotinib containing compositions
HUE034118T2 (en) 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
WO2013181251A1 (en) 2012-05-29 2013-12-05 Ratiopharm Gmbh Crizotinib hydrochloride salt in crystalline
CN104603620B (zh) 2012-09-24 2018-02-23 文塔纳医疗系统公司 使用间变性淋巴瘤激酶(alk)作为标志物鉴定治疗响应性非小细胞肺癌的方法
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
AU2015392050B2 (en) * 2015-04-23 2020-01-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fumarate of pyridylamine compound and crystals thereof
US10259816B2 (en) 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
WO2017201502A1 (en) 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN108727337A (zh) * 2018-07-03 2018-11-02 无锡富泽药业有限公司 一种克唑替尼中间体的制备方法
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4725489A2 (en) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Treatment of canine cancers
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4433445A4 (en) * 2021-11-15 2026-04-01 Broad Inst Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR INDUCING INTRACELLULAR ANTIMICROBIAL ACTIVITY AND FOR PREVENTING AND TREATMENT OF MICROBIAL INFECTIONS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH07109260A (ja) 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
CN1231473C (zh) * 2000-02-16 2005-12-14 神经能质公司 取代的芳基吡嗪
JP4251868B2 (ja) * 2000-08-11 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２−アミノピリジン化合物および医薬用途
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6992087B2 (en) * 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
CA2517256C (en) * 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
BRPI0514687A (pt) * 2004-08-26 2008-06-17 Pfizer compostos amino heteroarila como inibidores de proteìna tirosina cinase
ME01309B (me) * 2004-08-26 2013-12-20 Pfizer Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza
BR122020017756B1 (pt) * 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
DE602006018354D1 (de) * 2005-12-05 2010-12-30 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum

Also Published As

Publication number Publication date
DK1963302T3 (da) 2013-04-02
JP4663619B2 (ja) 2011-04-06
KR101146852B1 (ko) 2012-05-16
EP1963302B1 (en) 2013-02-27
US20080293769A1 (en) 2008-11-27
AR057964A1 (es) 2007-12-26
NZ568289A (en) 2011-06-30
RU2008120338A (ru) 2010-01-20
SI1963302T1 (sl) 2013-04-30
CN101326175B (zh) 2012-07-18
IL191971A (en) 2013-05-30
IL191971A0 (en) 2011-08-01
JP2007153893A (ja) 2007-06-21
US8217057B2 (en) 2012-07-10
AU2006323025A1 (en) 2007-06-14
WO2007066185A2 (en) 2007-06-14
ES2402419T3 (es) 2013-05-03
HK1126477A1 (en) 2009-09-04
CN101326175A (zh) 2008-12-17
TWI389902B (zh) 2013-03-21
CA2632283A1 (en) 2007-06-14
AU2006323025B2 (en) 2012-07-05
CA2632283C (en) 2011-06-21
EP1963302A2 (en) 2008-09-03
KR20080074950A (ko) 2008-08-13
RU2387650C2 (ru) 2010-04-27
PT1963302E (pt) 2013-04-09
BRPI0619420A2 (pt) 2011-10-04
ZA200804374B (en) 2009-12-30
TW200730522A (en) 2007-08-16
WO2007066185A3 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
IL191971A0 (en) Polymorphs of a c-met/hgfr inhibitor
ZA201004027B (en) Polymorphs of a c-met/hgfr inhibitor
HRP20130626T1 (en) Pyridinone compounds
IL192395A0 (en) Modified lysine-mimetic compounds
IL183961A0 (en) Novel pyridine compounds
GB0504995D0 (en) Use of a compound
AP2007004171A0 (en) Novel compounds
GB0521244D0 (en) Benzamide compounds
EP1868612A4 (en) NOVEL CONNECTIONS
EP1868611A4 (en) NOVEL CONNECTIONS
AP2007004282A0 (en) Derivatives of A 1-phenyltriazole as antiparasiticagents
GB0504314D0 (en) Novel polymorph
ZA200705419B (en) Novel pyridine compounds
EP1957657A4 (en) BIOMARKER OF ENHANCED INTESTINAL FUNCTION
IL186301A0 (en) Hydromorphone polymorphs
IL186143A0 (en) Pro-drugs of n-thiazol-2yl-benzamide derivatives
GB0518494D0 (en) Thiazole compounds
EP1869026A4 (en) NEW CONNECTIONS
GB0514685D0 (en) A ntineoplastic compounds
ZA200707966B (en) Pro-drugs of n-thiazol-2yl-benzamide derivatives
GB0522829D0 (en) Use of a compound
GB0512626D0 (en) Inhibitor compounds
GB0503944D0 (en) Comparison of patterns
GB0517677D0 (en) Inhibitor compounds II
GB0608095D0 (en) Novel compounds A3